JAN vs VTR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JAN and VTR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JAN and VTR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Janus Living, Inc. (NYSE: JAN) owns senior housing communities across the United States and, unusually for a healthcare REIT, takes the operating result of those communities rather than a fixed rent. Every property sits in a RIDEA structure, meaning Janus Living books resident fees and pays the operating costs, with third parties such as LCS, Sunrise Senior Living and Ciel Senior Living running the buildings under management contracts. The portfolio at June 30, 2026 was ~41 communities and ~11,420 units across ~13 states, weighted heavily toward Florida, which accounted for roughly ~51% of gross real estate assets, with Texas and Pennsylvania each near ~11%. A large slice of the portfolio is life plan communities, the entrance fee format where residents pay a substantial sum up front for the right to live on a campus that also offers assisted living and skilled care, which is why the balance sheet carries ~$699M of deferred revenue and another ~$227M of refundable entrance fees. Janus Living is externally managed by Healthpeak Investment Management, an indirect subsidiary of Healthpeak Properties (NYSE: DOC), and is headquartered in Denver.

Full JAN guide

Ventas, Inc. is an S&P 500 healthcare real estate investment trust that owns roughly 1,400 properties across North America and the United Kingdom, spanning senior housing communities, outpatient medical buildings, and research and lab (life science) assets. Its defining shift has been toward its senior housing operating portfolio (SHOP), which now accounts for more than half of net operating income and gives Ventas direct exposure to occupancy, rate, and margin trends rather than just fixed lease income. The company owns over 850 senior housing communities, and management has leaned hard into buying them, raising 2026 investment guidance to about $3 billion because acquiring communities has looked more attractive than building.

Full VTR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JAN drivers: Occupancy and rate, with almost no new supply arriving; An all-equity acquisition machine.
• VTR drivers: Senior housing (SHOP) demographic tailwind; Capital deployment into acquisitions.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Healthpeak controls about ~69.7% of the voting power and also supplies the external manager, whose fee is tied to the gross book value of investments acquired, which rewards balance sheet growth whether or not it earns its cost of capital. For VTR, as an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JAN if you believe its drivers more; VTR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JAN and VTR guides.

JAN. The reported price to earnings ratio for JAN runs into the hundreds and should be ignored, because first half GAAP income was dominated by a ~$46.3M gain on taking control of a joint venture and offset by ~$22.8M of IPO and transaction costs. FFO as Adjusted is the measure the company guides on, and at roughly ~$30 per share against guidance of ~$0.95 to ~$0.98 the stock changes hands near ~31 times, a premium to most diversified healthcare REITs. The ~$0.57 annualized dividend works out to a yield under ~2%, low for a REIT and a sign that the market is paying for growth here rather than income.

VTR. VTR trades around $96 with a market cap near $47 billion, making it the second-largest healthcare REIT behind Welltower. At roughly a mid-20s price-to-FFO multiple, the market is paying up for a fifth consecutive year of double-digit senior housing NOI growth. The dividend yield is modest for a REIT at about 2.1%, reflecting both the growth premium and a payout that management has been rebuilding since the pandemic.

Headline figures (approximate, August 2026): JAN shows revenue (ttm) ~$723M, q2 2026 revenue ~$216M, up ~45% year over year, ffo as adjusted (q2 2026) ~$0.24 per share, up ~40%, 2026 guidance, ffo as adjusted ~$0.95 to ~$0.98 per share; VTR shows revenue (ttm) ~$5.7B, q1 2026 revenue ~$1.66B, normalized ffo/share (q1 2026) ~$0.94, 2026 ffo/share guidance ~$3.82-$3.89.

JAN and VTR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JAN and VTR exposure against your real portfolio. It is not an investment adviser.